Post-exposure prophylaxis to prevent varicella in immunocompromised children

Area of Science:

• Immunology
• Virology
• Pediatric Infectious Diseases

Background:

• Varicella-zoster virus (VZV) poses life-threatening risks to immunocompromised individuals.
• Post-exposure prophylaxis (PEP) is crucial for preventing secondary VZV infections.
• Evidence for acyclovir (ACV)/valacyclovir (VCV) as PEP is limited.

Purpose of the Study:

• To evaluate the efficacy and safety of ACV/VCV as PEP in immunocompromised pediatric patients exposed to VZV.
• To compare VZV infection rates between patients receiving PEP and those who did not.

Main Methods:

• Retrospective analysis of immunocompromised pediatric patients with significant VZV exposure.
• Categorization of patients based on PEP received: ACV/VCV, intravenous immunoglobulin (IVIG), ACV/VCV/IVIG, or vaccine.
• Comparison of secondary VZV infection incidence between PEP and non-PEP groups.

Main Results:

• 107 patients received PEP (91 ACV/VCV, 16 ACV/VCV/IVIG); 10 did not receive PEP.
• Secondary VZV infection occurred in 2.2% of the PEP group versus 20.0% of the non-PEP group (P=0.036).
• No antiviral drug side effects were observed in patients receiving PEP.

Conclusions:

• Antiviral agents like ACV/VCV are effective and safe for VZV PEP in immunocompromised patients.
• Prompt virological diagnosis aids efficient PEP administration after VZV exposure.
• PEP significantly reduces the risk of secondary VZV infections in this vulnerable population.